<SEC-DOCUMENT>0001628280-21-021218.txt : 20211102
<SEC-HEADER>0001628280-21-021218.hdr.sgml : 20211102
<ACCEPTANCE-DATETIME>20211102165206
ACCESSION NUMBER:		0001628280-21-021218
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211102
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211102
DATE AS OF CHANGE:		20211102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		211372177

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aqst-20211102.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:86e05022-47a4-44ef-86c0-2e453112c803,g:38e97f17-9788-49bf-bf70-13a3a56b9b2f,d:ba6615f60bca464bacc751a917207107--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>aqst-20211102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN180L2ZyYWc6ODQwMGFmOTc2YzUxNGIzZGI3MmE5ZjgwYmY4YjQ4ODIvdGFibGU6NGU3ODFkYzExOTQ0NDY1MTllZjViZjQ0MjNlMTFlNmMvdGFibGVyYW5nZTo0ZTc4MWRjMTE5NDQ0NjUxOWVmNWJmNDQyM2UxMWU2Y18yLTEtMS0xLTA_ad11d616-dded-4424-9b8a-178f70f4d09f">0001398733</ix:nonNumeric><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN180L2ZyYWc6ODQwMGFmOTc2YzUxNGIzZGI3MmE5ZjgwYmY4YjQ4ODIvdGFibGU6NGU3ODFkYzExOTQ0NDY1MTllZjViZjQ0MjNlMTFlNmMvdGFibGVyYW5nZTo0ZTc4MWRjMTE5NDQ0NjUxOWVmNWJmNDQyM2UxMWU2Y181LTEtMS0xLTA_a2464407-6ee2-44f7-aab5-34ffb281d8e9">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="aqst-20211102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001398733</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-02</xbrli:startDate><xbrli:endDate>2021-11-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iba6615f60bca464bacc751a917207107_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU5_e60cf8a7-afcb-4c82-b562-6ffbda8da090">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8yMzA_0327e594-322f-40e6-971e-f64b64e9726d">November&#160;2, 2021</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDYw_358cbb18-9a50-426c-b2a9-dc142aaaf071">Aquestive Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NWFhNmUxZDJmZjMwNGE4NzhjYTE2MzNkYTEzNTZkOWQvdGFibGVyYW5nZTo1YWE2ZTFkMmZmMzA0YTg3OGNhMTYzM2RhMTM1NmQ5ZF8wLTAtMS0xLTA_8a9288c2-aa2b-40ce-93a3-ccebacbbabdf">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NWFhNmUxZDJmZjMwNGE4NzhjYTE2MzNkYTEzNTZkOWQvdGFibGVyYW5nZTo1YWE2ZTFkMmZmMzA0YTg3OGNhMTYzM2RhMTM1NmQ5ZF8wLTEtMS0xLTA_438bceac-b281-4754-954b-4115408e6653">001-38599</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NWFhNmUxZDJmZjMwNGE4NzhjYTE2MzNkYTEzNTZkOWQvdGFibGVyYW5nZTo1YWE2ZTFkMmZmMzA0YTg3OGNhMTYzM2RhMTM1NmQ5ZF8wLTItMS0xLTA_e938292f-977f-4f65-820a-eb52c422b8c3">82-3827296</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU1_b75153b9-5d06-4309-ade0-1bd92c6f660e">30 Technology Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU2_9b330e76-b7fc-49ec-b5fc-6cd48aa76f98">Warren</ix:nonNumeric>, <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU3_94caa16c-6f48-4775-9bf9-0b5f63b1b3e8">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDUy_0c7f3f81-f528-45ed-9aa2-67545148a1da">07059</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDYx_240b2f8c-d698-4205-980b-bfee359d469c">908</ix:nonNumeric>) <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDUz_b5f9ed00-a35e-458c-8534-f7c51c397b90">941-1900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">________________________________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:472.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY18wLTAtMS0xLTA_ea76c44e-8389-43e9-aefd-918e86037654">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY18yLTAtMS0xLTA_6a4a34fd-4a94-4f09-a6bc-f70d72d2d279">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY180LTAtMS0xLTA_fd89b963-e67f-4a9d-a26d-5757956067fe">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY182LTAtMS0xLTA_4d730e9b-3693-41d8-a164-a3687c528d57">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6MTRkYzJlNmFjNGEwNDNkMjk0ODllNWYwMGUzOWYxMWUvdGFibGVyYW5nZToxNGRjMmU2YWM0YTA0M2QyOTQ4OWU1ZjAwZTM5ZjExZV8xLTAtMS0xLTA_550d728e-5659-48af-a6c2-e4c5f5faee4d">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6MTRkYzJlNmFjNGEwNDNkMjk0ODllNWYwMGUzOWYxMWUvdGFibGVyYW5nZToxNGRjMmU2YWM0YTA0M2QyOTQ4OWU1ZjAwZTM5ZjExZV8xLTEtMS0xLTA_0c421537-3f8b-48d4-8bdb-693965ddabbc">AQST</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6MTRkYzJlNmFjNGEwNDNkMjk0ODllNWYwMGUzOWYxMWUvdGFibGVyYW5nZToxNGRjMmU2YWM0YTA0M2QyOTQ4OWU1ZjAwZTM5ZjExZV8xLTItMS0xLTA_3cdb61ea-bd35-419c-bffa-eb9da7f17bb0">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU0_2641be84-4900-491c-ad2a-8059fe6d0191">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU4_0c5803fd-19bd-45c8-aac7-5927a0c804c2">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iba6615f60bca464bacc751a917207107_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:454.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;2, 2021, Aquestive Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its reported financial results for the third quarter ended September&#160;30, 2021 and provided an update on recent developments in its business. A copy of the Company&#8217;s press release is attached hereto as Exhibit 99.1 and incorporated by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:454.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="aqst-q3x2021xex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press Release, dated November&#160;2, 2021, announcing the Company&#8217;s reported financial results for the third quarter ended September&#160;30, 2021 and providing an update on recent developments in its business.</span></div></td></tr></table></div><div><span><br/></span></div><div id="iba6615f60bca464bacc751a917207107_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November&#160;2, 2021</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aquestive Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ A. Ernest Toth, Jr</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: A. Ernest Toth, Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aqst-q3x2021xex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4adf2fba741044fcb79c2bd6dc4844c0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div style="text-align:right"><img alt="aqstlogo.jpg" src="aqstlogo.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:138px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Libervant&#8482; (diazepam) Buccal Film continues to progress through the FDA review process in advance of PDUFA goal date of December 23, 2021</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">AQST-109 top line Phase 1 trial demonstrates clinical results comparable to autoinjectors (such as EpiPen&#174; and Auvi-Q&#174;) for the emergency treatment of allergic reactions, including anaphylaxis</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Improves full year revenue and earnings guidance </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Hosts conference call at 8&#58;00 a.m. ET on November 3, 2021</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warren, N.J., November 2, 2021 &#8211; Aquestive Therapeutics, Inc. (NASDAQ&#58;AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients&#8217; unmet needs and solve therapeutic problems, today reported financial results for the third quarter ended September&#160;30, 2021 and provided an update on recent developments in its business. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We continue to interact with the FDA regarding the NDA submission for Libervant, including responding to several information requests to date, having a recent inspection of our post-marketing adverse event capabilities, regarding changes in language relating to our packaging, approval of the product trade name and an update to the patent information included in the resubmission.  We are continuing to prepare for commercialization with payer and sales force planning underway,&#8221; said Keith Kendall, Chief Executive Officer of Aquestive.  &#8220;We recently demonstrated clinical results comparable to the autoinjectors in the recently completed Phase 1 trial for AQST-109, potentially the first orally administered epinephrine product for the emergency treatment of allergic reactions, including anaphylaxis.  Before year end, we anticipate receiving written feedback from the FDA following our pre-IND meeting request and plan to commence an adaptive design crossover study that will determine the final formulation and dose strength leading to our pivotal PK study in 2022.&#34;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Libervant&#8482;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Libervant&#8482; is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures in selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity. The Company believes that Libervant, if approved by the U.S. Food and Drug Administration (FDA) for U.S. market access, will enable a larger share of patients to receive more appropriate treatment by providing consistent therapeutic dosing in a non-invasive and innovative treatment form for epileptic seizures. Aquestive is developing Libervant as an alternative to more invasive, inconvenient, and difficult to administer device driven products, including a rectal gel and nasal spray, for patients with refractory epilepsy.  A large portion of the patient population still does not access either one of these existing products and remains underserved with regard to having an important medication where they need it, when they need it and in a form they prefer. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Aquestive continues to actively engage with the FDA regarding its accepted New Drug Application (NDA) for Libervant ahead of the Prescription Drug User Fee Act (PDUFA) target goal date of December 23, 2021.  Aquestive has again spoken with and provided additional information to the  FDA Office of Orphan Products Development (OOPD) that the Company believes provides a clear position of clinical superiority as a major contribution to patient care as compared to the device driven rectal gel and nasal spray alternatives. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Epinephrine</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Aquestive continues to advance its development of product candidate AQST-109 (epinephrine prodrug sublingual film) for the emergency treatment of severe allergic reactions, including anaphylaxis, utilizing Aquestive&#8217;s PharmFilm&#174; technologies.  The Company reported positive topline data from its first-in-human Phase 1 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">pharmacokinetic (PK) trial for AQST-109.  Findings from this study support AQST-109's potential as the first orally administered and transformative epinephrine-based product for the treatment of allergic reactions including anaphylaxis with safety, tolerability, PK and pharmacodynamics (PD) measures comparable to those of the standard of care autoinjectors, such as EpiPen&#174; and Auvi-Q&#174;. These products require patients or caregivers to inject epinephrine into their thighs during an emergency allergic reaction. However, AQST-109 would, if approved by the FDA, allow a patient to simply place a dissolvable strip, approximately the size and weight of a postage stamp, under the tongue, again providing an appropriate medication where it is needed, when it is needed and in a form preferred by patients. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Aquestive has submitted its request for a pre-Investigational New Drug (IND) meeting with the FDA and anticipates receiving a written response from the FDA before year end 2021.  Aquestive is on track to conduct a crossover study using an adaptive design for AQST-109 beginning in the fourth quarter 2021.  This study will determine the final formulation and dose for AQST-109 and allow the Company to move forward to the manufacture of registration batches and a pivotal PK study in 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s proprietary product Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (clobazam), an oral film for the treatment of seizures associated with Lennox-Gastaut syndrome, continued to grow in shipment volumes to the prescriber base for the third quarter 2021. Sympazan has grown quarterly over the past eleven sequential quarters since its launch.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2021 Financials</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues were $13.3 million in the third quarter 2021, compared to $8.3 million in the third quarter 2020.  For the third quarter 2021 compared to the prior year period, the Company saw an 18% increase in Sympazan net revenue and a 77% increase in manufacture and supply revenue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Aquestive&#8217;s net loss for the third quarter 2021 was $14.6 million, or $0.37 loss per share. The net loss for the third quarter 2020 was $16.6 million, or $0.49 loss per share.  The year-over-year change in net loss was driven by higher revenue, lower costs and expenses, offset by an increase in non-cash interest expense related to the KYNMOBI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> monetization transaction, which does not represent a cash output or monetary obligation at any time during the life of the transaction.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adjusted EBITDA loss was $5.3 million in the third quarter 2021, compared to a loss of $11.3 million in the third quarter of 2020.  The year-over-year change in adjusted EBITDA was primarily driven by higher revenue and an increase in non-cash interest expense related to the KYNMOBI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> monetization transaction, which does not represent a cash output or monetary obligation at any time during the life of the transaction.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2021, cash and cash equivalents were $31.2 million.&#8239;During the third quarter 2021, Aquestive accessed capital under its &#34;At-The-Market&#34; (ATM) facility resulting in net proceeds of $6.1&#160;million.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On September 30, 2021, the Company entered into a waiver agreement with the holders of the 12.5% Notes (the &#34;Notes&#34;) pursuant to which the principal payment due under the Notes on September 30, 2021 was deferred in order to provide sufficient time for the execution of the Fourth Supplemental Indenture of the existing debt facility.  The Fourth Supplemental Indenture was subsequently executed in October 2021 which extended the date of the first amortization payment to March 30, 2023, resulting in a deferral of $10.3M in principal payments through December 2022. The Fourth Supplemental Indenture did not change the maturity date of the Notes or the interest payment obligation due under the Notes. As part of the agreement, the Company entered into a Consent Fee Letter pursuant to which the Company agreed to pay the holders of the Notes a $2.7&#160;million fee, payable in four quarterly installments beginning May 15, 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021 Outlook</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sympazan and the Company's other on-going business activities generated strong operating results during the first half of 2021.  As a result, the Company has revised its full year expectations as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Updated Guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prior Guidance</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenue (in millions)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$47 to $49</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$46 to $48</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP adjusted gross margins</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70% to 75%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70% to 75%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP adjusted EBITDA loss (in millions)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$32 to $34</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$39 to $42</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tomorrow&#8217;s Conference Call and Webcast Reminder</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company will host a conference call at 8&#58;00 a.m. ET on Wednesday, November 3, 2021. Investors and analysts may participate in the conference call by dialing (866) 417-5886 from the U.S. and (409) 217-8235 internationally, followed by the conference ID&#58; 4285256.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There will also be a simultaneous, live webcast available on the Investors section of the Company&#8217;s website at https&#58;&#47;&#47;investors.aquestive.com&#47;events-and-presentations. The webcast will be archived for 30 days.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Aquestive Therapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and has proven capabilities for drug development and commercialization.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non-GAAP Financial Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release and our webcast earnings call regarding our quarterly financial results contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP adjusted EBITDA loss, non-GAAP adjusted gross margins, non-GAAP adjusted costs and expenses and other adjusted expense measures, because such measures exclude, as applicable, share-based compensation expense, interest expense, interest expense related to the sale of future revenue, interest income, depreciation, amortization, and income taxes.&#8239; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Specifically, the Company adjusts net income (loss) for loss on the extinguishment of debt&#59; certain non-cash expenses, including share-based compensation expenses&#59; depreciation and amortization&#59; and interest expense related to the sale of future revenue, interest income and other income (expense), net and income taxes, with a result of adjusted EBITDA loss.&#8239; Similarly, manufacture and supply expense, research and development expense, and selling, general and administrative expense were adjusted for certain non-cash expenses of share-based compensation expense and depreciation and amortization. Adjusted EBITDA loss and these non-GAAP expense categories are used as a supplement to the corresponding GAAP measures to provide additional insight regarding the Company&#8217;s ongoing operating performance.&#8239; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">These measures supplement the Company&#8217;s financial results prepared in accordance with GAAP. Aquestive management uses these measures to analyze its financial results, and its future manufacture and supply expenses, gross margins, research and development expense and selling, general and administrative expense and to help make managerial decisions. In management&#8217;s opinion, these non-GAAP measures provide added transparency into the operating performance of Aquestive and added insight into the effectiveness of our operating strategies and actions. The Company may provide one or more revenue measures adjusted for certain discrete items, such as fees collected on certain licensed products, in order to provide investors added insight into our revenue stream and breakdown, along with providing our GAAP revenue. Such measures are intended to supplement, not act as substitutes for, comparable GAAP measures and should not be read as a measure of liquidity for Aquestive. Adjusted EBITDA loss and the other non-GAAP measures are also likely calculated in a way that is not comparable to similarly titled measures reported by other companies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non-GAAP Outlook</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In providing the outlook for non-GAAP adjusted EBITDA and non-GAAP gross margin, we exclude certain items which are otherwise included in determining the comparable GAAP financial measures. In order to inform our outlook measures of non-GAAP adjusted EBITDA and non-GAAP gross margin, a description of the 2021 and 2020 adjustments which have been applicable in determining non-GAAP Adjusted EBITDA and non-GAAP gross margin for these periods are reflected in the tables below. In providing outlook for non-GAAP gross margin, the Company adjusts for non-cash share-based compensation expense and depreciation and amortization. The Company is providing such outlook only on a non-GAAP basis because the Company is unable to predict with reasonable certainty the totality or ultimate outcome or occurrence of these adjustments for the forward-looking period such as share-based compensation expense, income tax, amortization, and certain other adjusted items, which can be dependent on future events that may not be reliably predicted. Based on past reported results, where one or more of these items have been applicable, such excluded items could be material, individually or in the aggregate, to reported results.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Certain statements in this press release are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the clinical advancement and related timing of Libervant and AQST-109 through the regulatory and development pipeline&#59; the potential for AQST-109 as the first orally administered epinephrine prodrug for the treatment of anaphylaxis&#59; the focus on growing the Company&#8217;s commercial sales of Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#59; the ability to address the concerns identified in the FDA&#8217;s Complete Response Letter dated September 25, 2020 regarding the NDA for Libervant&#59; obtaining FDA approval of Libervant for U.S. market access&#59; the timing of the PDUFA target goal date&#59; the 2021 financial outlook&#59; and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials&#59; on regulatory submissions and regulatory reviews and approvals of our product candidates&#59; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution&#59; sale of and demand for our products&#59; our liquidity and availability of capital resources&#59; customer demand for our products and services&#59; customers&#8217; ability to pay for goods and services&#59; and ongoing availability of an appropriate labor force and skilled professionals.  Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">These forward-looking statements are also based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans for AQST-108, AQST-109 and our other drug candidates&#59; risk of delays in regulatory advancement through the FDA of Libervant, AQST-108, AQST-109 and our other drug candidates or failure to receive approval, including the risk that the FDA may require additional clinical studies for FDA approval of Libervant for U.S. market access&#59; risk of our ability to demonstrate to the FDA the &#8220;clinical superiority&#8221; of Libervant within the meaning of the FDA regulations relative to FDA-approved diazepam rectal gel and nasal spray products including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved products, as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product of a competitor in the U.S., and there can be no assurance that the Company will be successful&#59; risk that a competitor obtains FDA orphan drug exclusivity for a product with the same active moiety as any of our other drug product candidates for which we are seeking FDA approval and that such earlier approved competitor orphan drug blocks such other product candidates in the U.S. for seven years for the same indication&#59; risk that a competitor will obtain other market exclusivity with respect to our product candidates&#59; risk in obtaining market access for our product candidates for other reasons&#59; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations)&#59; risk of development of our sales and marketing capabilities&#59; risk of legal costs associated with and the outcome of our patent litigation challenging third party at risk generic sale of our proprietary products&#59; risk of sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer term cash requirements and other cash needs, at the times and in the amounts needed&#59; risks and uncertainties concerning the royalty and other revenue stream of the KYNMOBI&#174; monetization, achievement of  royalty targets worldwide or in any jurisdiction and certain other commercial targets required for contingent payments under the monetization transaction&#59; risk of failure to satisfy all financial and other debt covenants and of any default&#59; short-term and long-term liquidity and cash requirements, cash funding and cash burn&#59; risk related to government claims against Indivior for which we license, manufacture and sell Suboxone&#174; and which accounts for the substantial part of our current operating revenues&#59; risk of eroding market share for Suboxone and risk of a sunsetting product&#59; risks related to the outsourcing of certain marketing and other operational and staff functions to third parties&#59; risk of the rate and degree of market acceptance of our product and product candidates&#59; the success of any competing products, including generics&#59; risk of the size and growth of our product markets&#59; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities&#59; risks associated with intellectual property rights and infringement claims relating to the Company's products&#59; risk of unexpected patent developments&#59; the impact of existing and future legislation and regulatory provisions on product exclusivity&#59; legislation or regulatory actions affecting pharmaceutical product pricing, reimbursement or access&#59; claims and risks that may arise regarding the safety or efficacy of the Company's products and product candidates&#59; </font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">including anticipated sales of Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#59;  risk of loss of significant customers&#59; risks related to legal proceedings, including patent infringement, securities, investigative and antitrust litigation matters&#59; changes in government laws and regulations&#59; risk of product recalls and withdrawals&#59; uncertainties related to general economic, political, business, industry, regulatory and market conditions and other unusual items&#59; and other uncertainties affecting the Company described in the &#8220;Risk Factors&#8221; section and in other sections included in our Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, and in our Current Reports on Form 8-K filed with the Securities Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">PharmFilm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, Sympazan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.   All other registered trademarks referenced herein are the property of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Investor inquiries&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ICR Westwicke</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Stephanie Carrington</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">stephanie.carrington&#64;westwicke.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">646-277-1282</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:70.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,807&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,643&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,210&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,625&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,197&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,836&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,293&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,884&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; deficit</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,215&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,569&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,725&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,039&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,104&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,673&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,329&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,524&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,316&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,945&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,638&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,381&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingencies (Note 19)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value. Authorized 250,000,000 shares&#59; 40,083,245 and 34,569,254 shares issued and outstanding at September&#160;30, 2021 and December 31, 2020, respectively</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,466&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,725&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227,851)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186,257)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,345)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,497)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,293&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,884&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,287&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,260&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,754&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,700&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and supply</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,623&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,647&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,461&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,129&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,803&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,494&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,041&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,764&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,947&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,968)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,781)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,010)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,247)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#47;(expenses)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,787)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,778)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,305)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,296)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to the sale of future revenue, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,767)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,567)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other (expense) income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,551)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,415)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,551)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,415)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,551)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,415)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding - basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,224,863&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,619,379&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,297,892&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,592,846&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - Net Loss to Adjusted EBITDA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,551)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,594)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,415)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based Compensation Expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,625&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,787&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,305&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,296&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense related to the sale of future revenue, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other (income) expense, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and Amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-GAAP adjustments</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,223&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,945&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,130&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,332)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,262)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,649)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,285)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Expenses to Adjusted Expenses</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,041&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,764&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,947&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,765)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,128)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,625)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(736)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(754)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,233)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,337)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted costs and expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,619&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,522&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,403&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,985&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_25"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Manufacture &#38; Supply Expense to Adjusted Manufacture and Supply Expense</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands, except percentages)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacture and Supply Expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,623&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross Margin on total revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,744)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,163)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted manufacture and supply expense</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,733&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,638&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,878&#160;</font></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-GAAP Gross Margin on total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Research and Development Expense to Adjusted Research and Development Expense</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development Expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,260&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,647&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,461&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted research and development expense</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,445&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,817&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i4adf2fba741044fcb79c2bd6dc4844c0_31"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AQUESTIVE THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Non-GAAP Adjustments - GAAP Selling, General and Administrative Expenses to Adjusted Selling, General and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administrative Expenses</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General and Administrative Expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,129&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,803&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,494&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,310&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,510)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,217)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,125)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling, general and administrative expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,441&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,215&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,948&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,130&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>aqst-20211102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:86e05022-47a4-44ef-86c0-2e453112c803,g:38e97f17-9788-49bf-bf70-13a3a56b9b2f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:aqst="http://aquestive.com/20211102" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://aquestive.com/20211102">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20211102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aqst-20211102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://aquestive.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>aqst-20211102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:86e05022-47a4-44ef-86c0-2e453112c803,g:38e97f17-9788-49bf-bf70-13a3a56b9b2f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_5d51f982-256d-42e7-acc1-b04a6caf8e50_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4c9fd158-8904-45d3-aa13-41a834406021_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_308cfc2d-b1c7-4ac4-8c9f-c0339d09d579_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_62a8e474-f604-4bc3-a57b-f99f7a10667e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3447dde9-f32b-4f11-9b81-61d1cbdeb820_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a612db0b-b89e-4a33-8540-6e42c6c2073c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_520465ef-506a-4bda-b4a6-1a00de0eb020_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e3d77092-bf67-44ed-8491-e90d436f0a46_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_586f435a-b1a5-44c0-a8a5-014a0eef2afe_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_91011011-90b1-4d6c-9cac-62ebc7208347_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9b795cb6-d2c8-4ff1-a174-a163cc3d295c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1b92585c-6cf3-4d72-96c6-da41868bd72e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d0b2d853-ea47-4a1e-9751-9768bd4de82b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7aee3c8c-c05c-44b4-a37b-6f12ed91ac20_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_27b1a7cc-ee5c-403b-91cb-797866d94710_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6fbddbdb-b388-4c4e-ae23-f0e72c709f42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6ea0a085-eda0-4ed3-995e-451b89bedd70_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f094900e-c4b1-4aa2-91d1-8252a9573eac_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_615499c5-0242-4a1a-9f51-5f9eba659b30_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_33f2fe07-28a1-4bbb-b948-b38e561a0fc9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4668bec7-4925-4eb7-a172-1b1a9e88e0f6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c7d6735b-6996-4eec-88a7-8f7c7b4787a8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_ba3577da-13c1-4c71-b780-54d70aadd2ed_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>aqst-20211102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:86e05022-47a4-44ef-86c0-2e453112c803,g:38e97f17-9788-49bf-bf70-13a3a56b9b2f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aquestive.com/role/Cover" xlink:type="simple" xlink:href="aqst-20211102.xsd#Cover"/>
  <link:presentationLink xlink:role="http://aquestive.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_127242f8-9fa2-4cfb-b6b7-0bd8dafb4bb1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_DocumentType_127242f8-9fa2-4cfb-b6b7-0bd8dafb4bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b0156f94-1f26-4d91-b9a0-9c2b68ba88fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_DocumentPeriodEndDate_b0156f94-1f26-4d91-b9a0-9c2b68ba88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_faab5cfa-beb3-4b77-b94c-a77523b7c9a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityRegistrantName_faab5cfa-beb3-4b77-b94c-a77523b7c9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d9d3c62f-c2b8-46d1-800d-ae98afaa3335" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d9d3c62f-c2b8-46d1-800d-ae98afaa3335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b00087c2-6be3-41bb-9322-bcddac234937" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityFileNumber_b00087c2-6be3-41bb-9322-bcddac234937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d96ca819-ecae-4dc6-a669-9d9ee5f897e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityTaxIdentificationNumber_d96ca819-ecae-4dc6-a669-9d9ee5f897e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a2286252-5ca0-4783-898c-67356e063127" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityAddressAddressLine1_a2286252-5ca0-4783-898c-67356e063127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b1c650b-d9cb-48db-a6cc-3c691048c348" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityAddressCityOrTown_9b1c650b-d9cb-48db-a6cc-3c691048c348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_99d50179-69e9-462e-aa2f-4b8081fa3704" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityAddressStateOrProvince_99d50179-69e9-462e-aa2f-4b8081fa3704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dfdfab11-9669-45ff-a986-6e2d30c3b030" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityAddressPostalZipCode_dfdfab11-9669-45ff-a986-6e2d30c3b030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a3bd7e76-7ff0-473a-8434-fbc06ad4a363" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_CityAreaCode_a3bd7e76-7ff0-473a-8434-fbc06ad4a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f7ae9377-397a-46e0-9ff2-3bdb12faf8f8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_LocalPhoneNumber_f7ae9377-397a-46e0-9ff2-3bdb12faf8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a411900c-c035-4d69-8af1-c189a8d00c10" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_WrittenCommunications_a411900c-c035-4d69-8af1-c189a8d00c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b69df805-1d3b-4edd-b392-0283683bae38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_SolicitingMaterial_b69df805-1d3b-4edd-b392-0283683bae38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1e5c57ca-cbc0-4d2c-baeb-5c692071a1ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_PreCommencementTenderOffer_1e5c57ca-cbc0-4d2c-baeb-5c692071a1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5adabd18-8665-4341-80bf-042d47cb3e9d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5adabd18-8665-4341-80bf-042d47cb3e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5fa7b6c6-b1d2-4063-ae94-1df2f18b0cd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_Security12bTitle_5fa7b6c6-b1d2-4063-ae94-1df2f18b0cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bc5a3d13-e79d-4575-b801-9799117610e6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_TradingSymbol_bc5a3d13-e79d-4575-b801-9799117610e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f368cb4d-e496-4eab-8197-b32a6a64f2d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_SecurityExchangeName_f368cb4d-e496-4eab-8197-b32a6a64f2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3ea46a7c-b197-4d04-b559-f19510530b10" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityEmergingGrowthCompany_3ea46a7c-b197-4d04-b559-f19510530b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_29fa9ea6-058d-4972-9d6c-8a679d21858f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityExTransitionPeriod_29fa9ea6-058d-4972-9d6c-8a679d21858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e84f2fde-ec27-47fb-81b4-e247317b7c5f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_EntityCentralIndexKey_e84f2fde-ec27-47fb-81b4-e247317b7c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f0edb2fb-b613-40ee-9809-0dbebbfa20a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e8c891cf-506c-43ec-94a4-a96f26662493" xlink:to="loc_dei_AmendmentFlag_f0edb2fb-b613-40ee-9809-0dbebbfa20a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>aqstlogo.jpg
<TEXT>
begin 644 aqstlogo.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A;6%N=&AA
M+DUA<VME    !9 #  (    4   0J) $  (    4   0O)*1  (    #-S<
M )*2  (    #-S<  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C Z,3(Z,#,@,34Z-3DZ,#0 ,C R,#HQ
M,CHP,R Q-3HU.3HP-    %, 80!M &$ ;@!T &@ 80 N $T 80!S &L 90
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !F :,# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M1SA54NQ/H.37R-XP^(WB&[\6Z@]IJ4BPI.Z1K&>-@)Q^E SZ\+_W2/Q-+O\
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MZ/&9>N=QQ^6:B\<Z18Z5\-=4AT^UC@00-]Q<$_*>] 'REX2&/&FBX_Y_X?\
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M+:QA<21N2"1CTQ7O:9VC-?-8NT:W/!GN8=2<.69XK=?#348?$"00JSVK-E9
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M% !M%&*** %Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
FQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>aqst-20211102_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aqst-20211102.xsd" xlink:type="simple"/>
    <context id="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001398733</identifier>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN180L2ZyYWc6ODQwMGFmOTc2YzUxNGIzZGI3MmE5ZjgwYmY4YjQ4ODIvdGFibGU6NGU3ODFkYzExOTQ0NDY1MTllZjViZjQ0MjNlMTFlNmMvdGFibGVyYW5nZTo0ZTc4MWRjMTE5NDQ0NjUxOWVmNWJmNDQyM2UxMWU2Y18yLTEtMS0xLTA_ad11d616-dded-4424-9b8a-178f70f4d09f">0001398733</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN180L2ZyYWc6ODQwMGFmOTc2YzUxNGIzZGI3MmE5ZjgwYmY4YjQ4ODIvdGFibGU6NGU3ODFkYzExOTQ0NDY1MTllZjViZjQ0MjNlMTFlNmMvdGFibGVyYW5nZTo0ZTc4MWRjMTE5NDQ0NjUxOWVmNWJmNDQyM2UxMWU2Y181LTEtMS0xLTA_a2464407-6ee2-44f7-aab5-34ffb281d8e9">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU5_e60cf8a7-afcb-4c82-b562-6ffbda8da090">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8yMzA_0327e594-322f-40e6-971e-f64b64e9726d">2021-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDYw_358cbb18-9a50-426c-b2a9-dc142aaaf071">Aquestive Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NWFhNmUxZDJmZjMwNGE4NzhjYTE2MzNkYTEzNTZkOWQvdGFibGVyYW5nZTo1YWE2ZTFkMmZmMzA0YTg3OGNhMTYzM2RhMTM1NmQ5ZF8wLTAtMS0xLTA_8a9288c2-aa2b-40ce-93a3-ccebacbbabdf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NWFhNmUxZDJmZjMwNGE4NzhjYTE2MzNkYTEzNTZkOWQvdGFibGVyYW5nZTo1YWE2ZTFkMmZmMzA0YTg3OGNhMTYzM2RhMTM1NmQ5ZF8wLTEtMS0xLTA_438bceac-b281-4754-954b-4115408e6653">001-38599</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NWFhNmUxZDJmZjMwNGE4NzhjYTE2MzNkYTEzNTZkOWQvdGFibGVyYW5nZTo1YWE2ZTFkMmZmMzA0YTg3OGNhMTYzM2RhMTM1NmQ5ZF8wLTItMS0xLTA_e938292f-977f-4f65-820a-eb52c422b8c3">82-3827296</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU1_b75153b9-5d06-4309-ade0-1bd92c6f660e">30 Technology Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU2_9b330e76-b7fc-49ec-b5fc-6cd48aa76f98">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU3_94caa16c-6f48-4775-9bf9-0b5f63b1b3e8">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDUy_0c7f3f81-f528-45ed-9aa2-67545148a1da">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDYx_240b2f8c-d698-4205-980b-bfee359d469c">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDUz_b5f9ed00-a35e-458c-8534-f7c51c397b90">941-1900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY18wLTAtMS0xLTA_ea76c44e-8389-43e9-aefd-918e86037654">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY18yLTAtMS0xLTA_6a4a34fd-4a94-4f09-a6bc-f70d72d2d279">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY180LTAtMS0xLTA_fd89b963-e67f-4a9d-a26d-5757956067fe">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6NTBjMTg5OGJjMmNkNGQ2YWExNDM0NTcyZDNhNDBhMWMvdGFibGVyYW5nZTo1MGMxODk4YmMyY2Q0ZDZhYTE0MzQ1NzJkM2E0MGExY182LTAtMS0xLTA_4d730e9b-3693-41d8-a164-a3687c528d57">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6MTRkYzJlNmFjNGEwNDNkMjk0ODllNWYwMGUzOWYxMWUvdGFibGVyYW5nZToxNGRjMmU2YWM0YTA0M2QyOTQ4OWU1ZjAwZTM5ZjExZV8xLTAtMS0xLTA_550d728e-5659-48af-a6c2-e4c5f5faee4d">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6MTRkYzJlNmFjNGEwNDNkMjk0ODllNWYwMGUzOWYxMWUvdGFibGVyYW5nZToxNGRjMmU2YWM0YTA0M2QyOTQ4OWU1ZjAwZTM5ZjExZV8xLTEtMS0xLTA_0c421537-3f8b-48d4-8bdb-693965ddabbc">AQST</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGFibGU6MTRkYzJlNmFjNGEwNDNkMjk0ODllNWYwMGUzOWYxMWUvdGFibGVyYW5nZToxNGRjMmU2YWM0YTA0M2QyOTQ4OWU1ZjAwZTM5ZjExZV8xLTItMS0xLTA_3cdb61ea-bd35-419c-bffa-eb9da7f17bb0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU0_2641be84-4900-491c-ad2a-8059fe6d0191">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhNjYxNWY2MGJjYTQ2NGJhY2M3NTFhOTE3MjA3MTA3L3NlYzpiYTY2MTVmNjBiY2E0NjRiYWNjNzUxYTkxNzIwNzEwN18xL2ZyYWc6NzAzMTcwNGY3YzViNDMxMjhhYTgwZTBkN2MzMThmNWYvdGV4dHJlZ2lvbjo3MDMxNzA0ZjdjNWI0MzEyOGFhODBlMGQ3YzMxOGY1Zl8xNDU4_0c5803fd-19bd-45c8-aac7-5927a0c804c2">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140499945005208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aquestive Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3827296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30 Technology Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-1900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AQST<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001398733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M HHO_A!\;8[NB>O*0JE7UWB*;EN^(^()#ZV38'!YXV.>)$X).+[O15OE;[K
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M*Y>E7T#!QLY!,B9KQ[9!T.H<';?*YRENTP>R#8$1A -DL?G9[<!KL7"UIFE
M*]NGN&/ON<8P137X_Q/,S@WYQ.MSA4OY4.WM?J_;;F-DE?W3ADT\V$946,=C
MPE:U//_3]KVCLZD[YW]AKEH,2?@2A/RK+NCJW=%YU[ J*XZK"V7A\%O<QIR!
MC[D/X/U2*7MHN!-P^0^,X3]02P,$%     @ @H9B4Y^@&_"Q @  X@P   T
M  !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV
M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S
MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.
MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#
M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6
M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H
MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_
MC!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK
M'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?
MK7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*
MLN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-
MM[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]
MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7
MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L
M"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9G
MD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ @H9B4Y>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (*&8E.SFMBU2@0  ,P0   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " ""AF)3GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( (*&8E.7BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (*&8E.JQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" ""AF)3)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ""AF)399!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aqst-20211102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aquestive.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="aqst-20211102.htm">aqst-20211102.htm</File>
    <File>aqst-20211102.xsd</File>
    <File>aqst-20211102_lab.xml</File>
    <File>aqst-20211102_pre.xml</File>
    <File>aqst-q3x2021xex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aqst-20211102.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "aqst-20211102.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aqst-20211102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aqst-20211102_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aqst-20211102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "aqst",
   "nsuri": "http://aquestive.com/20211102",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aqst-20211102.htm",
      "contextRef": "i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://aquestive.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aqst-20211102.htm",
      "contextRef": "i215dc9fb612d4154bdf48024cad947a4_D20211102-20211102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aquestive.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-21-021218-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-021218-xbrl.zip
M4$L#!!0    ( (*&8E-KWVY9A!0  -^0   1    87%S="TR,#(Q,3$P,BYH
M=&WM/6M7VDK7W\^OF)?SON>Q:SF0R3W8^BRKZ+&GA(JQ'OCBFF0F$@R$)D'!
M7__N20*"X*WUAM6N50ASVS/[OO?,Y.-_1[T0G?,X":+^IQ(I2R7TW\V/_X/Q
MOY^;7]%.Y U[O)^B[9C3E#-T$:0==,QX<H;\..JAXR@^"\XIQEF;[6@PCH/3
M3HID22;7"N.JJ7-)DV09JP95L:IR'YNZ)V&9JYI"B.R9DK)^6E5,;AD^,;!E
MF"96+=?'KF](F"A4H9KN6J[LK[.J2W6=:+XNN1Y5==6EGF=HA%K$D"6#2(88
MMI/"[&"&_:0Z<N,P^%3JI.F@6JE<7%R4Q2_E*#ZMR)*D5()^DM*^QTN3^F'0
M/YNK?Z%DM8EE696L=%HU"995A&Y)Y=_ZUT.OPWL47Q\@&-T$#1'0P !<X&!2
M?0&<>?!%L4N3:>^,7\&4U4RX5SZ-SBM0 "UD"4L$*Z2H?O,\Q0I>09PNA^ *
MVDH:TW[B1W&/ID!1Q4@R)O),)QA@F>MH MMM_1 -2^8$XFI(^Z>?2KR/CPY+
M@&9.V>;''D\I$KUB_F,8G'\J;4?]%(@7.^,!K(N7/WTJI7R45K)Y53;_^../
MCVF0AGR3_DA2+,B6$$G^6,E__%C)NW8C-M[\R()SE*3CD'\JL2 9A'1<[4=]
M#@ $HZJHR./\:\ 8[V=?H=P&#HH#+Q]_E#:Y_ZD4R$1CGN6[.I&92C359;YJ
M2K+J468)[CC9F8 RA:F$^K0GAN9!M=8'^,;;,)V8AOM]QD?_\'$)!0RZ9LKW
ML;L3G7^5F^<MI3YDW=IY>\_J-GI?.G:W-;*/6W)][TNWY1S(]MZ7#CPIMK/;
M:3@UI=[=4NK.EO)5L</6Y2!H.5#J?._9W<]!2ZY)=K<9M([MKGUY-&HY9R/[
M<O_"OJQ=V,24OLKM<>O8TQL[!Q?UO=U>P_'D%M2S]_8OVWO[2KU7T]K=TXM6
MKZ6VN@=J8V?_G.WM!N[>D6[O'2F-G=VSUF5MU' .)'NG1>I.&+:[WX-V]T"J
M=^VP[NR&=J]>M/D.8VG]MA-);<=3Z\?-;MVI:?8.M.T>C1K' //QEQX\C^OR
MT:A^?"2WB#G^ZM32^J$T^NILG5!&"-.)C@%9#*21K&++-2DFA@G2QE>99/FE
M30F86+%,0U$^5N;P^93HW0*9RX3<W0WIZ3M:[T(KF4.K#,I !?&O<PZ:1O4-
M3*FK847U?5<V"0/M4MKT:9CP!8Q6YIDWYCZ/.8CL9(G,$0*WFF2B'7".,H50
M34'2?"HE06\0"DF<_=:)!4G,B9?R*&'0166^CWS\JT$+&))H&&=/F0:K%G26
M$\7/T-FD(Y[)D,E3P,2S'_ 890#QI0)Z>_^?>9:XWGAS\M-\[P-8WXA-GD /
MQND.V!.; BA,"!82]WK9%$QV0]5)R>1Y,DAE;J$FJSI=QLJ,L*Z 2,_E>K:<
M=YD4)Z0TVZ;0!;V@CSM<F#U58@[2C8N I9TJD:3_*V7U-C\F PH4Y<85:)U_
MSSM9[(K&I]!;&@VJVB"%YBEU0SXI=:,8H,9>%(9TD/#JY,O&1!OE^A-GC3:*
MOMPH3:.>Z&X#S+PT\&B(:1B<]JMB=8KB F;+*IN:(L!.87%2-AFXF%$YFU$E
M98MEEEFVI)N+I3*9EE6RON-)A6+EK'RZ#.1H*);H4TDI79MW,1,R2%$2A0%#
M?TK9WT91+E:-E+6%X@%E+.B?5B5$LD&NH*AD*[4$#]G2Y*OD 27SN)0C<5(.
M0$9Q=3* #Y2&?=H+PG'U/T[0 WEA\PO4C'JT_Y_U! P9L'CBP,\K)L$EKQ(5
M\)$]7N3S-Z"?#'D32I+%:A[9^TYM!QTZ6T[M<)YV7B&TA[7MH^:^LU\[1%OV
M#JK]N_WWEKU70]N->GW_\'"_8;_@%.1[3>&8)AV@E33JKZ.=;7!C--5: /IF
MAL[^>UZ>!3E3EG+6>W:F57Z2:5\G2YKWHI#=1K..GM#VF[C<N=/RDJ;?:&+Z
MV9=;EW7'N[#W6DKK\GM@[]1']6ZGTW).+]K.YS-;KD-Y!TRS%IAQWU7V]Y>P
M+8?G;C=2ZE 7VDOM+NO:Q_M2_;(V;NP!;#N?P_K> ?17'S7V6J0=FB-[YT@[
MX;KD^28%J\WW7*QZIHQ=39>Q#N8;HR:CDB65-DW\SZ+U]D#9\L[ ;XR!I7LQ
M,.BH9LUV4+/VK=%T'B;<7]M<OATU#X^V8#). X'V=4#%(J*@1A,1;8U]0(U=
MY/Q=>_73F#$<ID;#UK8CP">6HJXVCH2/@B(?-?D@BE.T-GGF%+P4GJ2(GXL(
M:YP5<_:A^OC:)8^C0>M16F4P/.Y!EQVA<S"C8SP&4##O+]-"WS*?JI9[6K^7
M.AK7+[=.)$4VN&:I6)%E'ZL2U[%E$(Y]\ YUE5N&K(,G;T?GO.?R^*\_B2YM
MR.M9^/M._?2N:%94T<C7W2%U*>,_>?RWR4^#1 3*4QM*?B_N!&.Q=7&B:*;G
MNL3$%M4DK,JZAUV96IAY1)4II;YDD-+FUH\AR-G@G".GPV,ZX$-@E&0=[?>]
M\B];D<^M3M9J(^JE&2WD6F5" X@F*!EP3\3A& KZ*$@3Y'4H*)7XP[OP>2;A
ML[(1/$4N$T6[URH_L%M3-QZ_6U+6+?,A-'$3 4QP+ ]& LL;"WR^L.C1X/E9
M7WH2A3)C%XJ<K B^IWP01^="NLP;A+G& 8D9Q6"G9DG90U%[.QKVTWB\';'5
M5$!%HNIXMV/WCD;MG2^]=K<.;6NJ?=D!&&M0VSZ#STO;:9\UC@^N)ZI(Z[@F
MMYW=LWJOW0.348)QE,:>W:D[H*[D)GS6B=T[T-J[YL579VN:J#*I)9NF)V-*
M91=,2X]C2Z$*]CSN4M!J%% (W@,/Z06-E^2J"H%>D/\[9=]J*NT&(8?>P49_
MI])[4.E5.E553-?C5-A5)L&JH:G8 AQ@E0 J))/KNJ:(E"#!BJE9UCN9_A*9
M.G2T7^12O4S&OM/LO6EV?TJSW%),V0)_W3(,<-I]7<.F+%',74WV5%EV30]H
MUI2!9&5#MO1;B?;MF ]KF<)&48P:*?A!Z,LP#A(6>(+.A"LQI]RS:O$I[0>7
MV?.'M\7):]M1KQ<D8M<C$KH!Y8SVUF:Y7VZ6#\NHUAN$T1A0/B]<D!V5/RP2
M^X)OLU+AUB>7T5N,Q3Q)BH^O  !92?G\2WDZ<N(:&M$4U\(:DW2L*I*%*>,2
M)BZS9$_W=5WBI4U%0@[W.GU _ND8[<3!^<V6[.].4=OPM1$[T47_]Z,G^<1R
M%47BAHY=P_>P:G$P.37XIGM,-2DU=-\RQ?Z,..;]ZR2T_I0)^3D<92JT$7\#
M'SG(]G+_;HA23BQ8.$ITP PL(W@$AH8MU[>P!.C2%9>X"@=$V5^N(^G9</0M
M2E(:MH/!R@8E?@E#XQ/),WS%!W?-UV3 D,89MBB5L0[>FT: FPBCX+,9DG:S
MO_9:A?':$U*1$,!;,:>_)=VT1B>R*KFR;WJ8Z1;0C2P!9YN2BUV?<T6SF*I;
M7FG3DLSK5//A*7G[:P2F]+=.U%_E ,XO<?3E"8A6BS-)PE31.' TX,C4%!7[
MAJ<13[$,5VR*LE2"B25)J\?4A>3.4G+A4+A7".0W$HRXCFB?@1$9\H&@@<)1
MFZTI6+:H.I<0^^M/4R;&1H*^Q:"K@P$-46W$O6&6"6SXX 7Q9%EB;(6<'3M*
MT=9@$()#!R[;JP=W;3>*@22+Y&6<Y1_@D4ZP'_@B8=D_Y0PEPKQ"(4TF.V,6
M,;4DY2;@N&MWWZ-._/J>T>4[ 4Y>Z.^I9[^ ]N73W^YP[PRE'8[H8!!'@S@0
M<2@W&B&7A]&%0+LH%,2!3/P/\H-0\'60H$ <V6- #FD$%-$;ABGM\VB8A&.4
MT#1(_''6LF@0N4#B=!+.$@7Q579\"/T J?7'DS(_"F%PT4YDO (1"DJJ]R&R
ME\CK:H24M9RX;TCL7B6H%W*E:MG0;BZ^M>VMA:HAW[_GY:EYHMV2F[\ETA9R
M?W'5GB'.MD#@SY.8=:,H="G0:PI<,VL<'<=!"BPBHIG#?A'62U;20BK2!<[G
M;MTYU1H 5[UGG]E[!W+KN 964%VR'6_<WK$[]L[G3OUXX<0@J>^!U;1SIK9Z
M]7%+/I#:.VT8JP;6U0&Q+[^<U0'N^EYMU"+SB5A.#=U358Y-Q;2PJG +4^Z#
MST1,;NJ28NB:6MK\ZT_+4-6-QTUP+2/CG.]?B)(+>H)IS!(4&@SC9"BD*,CA
MYA#DGBIKA405HO00K"IH&  <6UZ*UHB!MG>;2%:D,E1<$F)^T!:=I;MP'E#U
M7?(\A>0YC,#J!)SW3^N@S4&EA^]BYRZQ,YX5.SI5J:*"G%&II6+5%P%TW?7
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M_$2$OY6F% PHAF!E.-@G5+@\G< -4F19Y1R:8'I_"-0#@VOZ)I,'NCFOCF2
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M[E35-NZ*_X=49OEMEI<+W/*XR%EVEQ;Y8WG8-]0<<A@%0"L. ='*!XP%&I
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MGC\2[X .[+RZ.=&_]/_7V'GU/U!+ P04    " ""AF)3WG1#7_DY   =,P,
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MU["','J=KH_?-$9\ZOD/K_]YZTU%S-Z+>_8QG/+@GT8,]-Z(1>2-Y(.Q][<
M2 *\Z9_W\G@]6(>0HXYK6@BL=U\FWM!+V&#0-!=)XS&R>?P<WG3,N)_\ZP7_
M*T[\<!PV_SL; R@C9^6C102T9U]V(IIV?_;EQ>[[=H S171X!)@6(.#JK[F(
M$^].L-N)B/A,S.&P,?LH9F&4Q/"A%[GLCSF/8(M2OOSD!3QP/.[#0_'<3V*#
M?8C".P^$$OL1!92(8_9IYH+ 8CQPV?5T!E_#ES_-?9_]C^ 1^WGNN;"&V GC
MBM@;OA@!SKIP2H*E%[@ Q]<-LS_;/S&;2["TU\+RNV_ZEM6]3'=^^"U<+L#&
MM)LF"=%?O:&([GB0P ;MOG7)+ER/_RUF?/H2,.8 ;0-2_2D(GB#Q J 'EH0,
MD#:.$)7)) KGXPG\5["?WEZQ2-QYL%GXWL&OO8!Q]PZQR<(1^_#VTT]7;!S"
MDD0 \-%;X8CI$*FG;1 %:<SN#;-7?]S<-LS6 ! V8_@;]F'"8\%,ED3(H:Z8
MAD&<1("*F#GP  HRP"#Q+>![.N,1*5A .)\GH1?\5SA)&,7L(IX[$\9C]F[F
M?1#!=]^8/?N2^/EJ?N<U_I ?O&2C,"+*$%,1C47@/,";P58AJP60SWT?/O<<
M>"=WT"8":>$%CC_'P\!R?#9Y\/D7+ZX749#N.BY1P!8V$$4F<$<H<!]0X +/
M"F!LPA_\.X ?Q6RLI##3L-\;[/\=QL18P4A$ F$+_.8SGK#^=]]T^I>M%N/-
M:9.]NV5AP-X#ED@R;A*,)0V)_\Y!DX\>CH22/WD$1S;8^^;_:QKYV2QY-H88
M,\U+MM[@,-AUX#39Q?NKF[=7?Q"L4+:]-!AGLPF/IMRA!T%ZD=0*'D#R./,8
M?"( I OD[8<S*5+0@)Z"-$(3Q?L;/W.]$:$C\<B) NYPYTZ"F@T0 V@D-3?C
MB0>/Q+3/WB6;!U.1L$ (-Z9%P>*&/2?YGG$=$)U3V'L2NOP!F QM)GC!*+.0
M4DF;2LF$S*F_E#DE@(]<=B-F"8$*1&JW==EN*8#A2V?2L'+A'VPN32HX;B30
M9$Q/C:*6U+ '_QDJ ZRYRM2U(B;B[];EGR(S2E!%>6@H@QYA]UY2-$C&/")]
M@I^\AT_B^7#JQ3&H&X)\9O\4=0^@9A8&\F<ABP&6$2#,"^ '4XZ:"IX@4B5K
M"$%OL F_(QI+,> %\4R06D-=%\XC-@/^;X /\5DD]*0+RX(^1O$+7CR?\:'G
M>T!H0#3YMIT)#\:"<.C#W^9\+.!;GR=J<[0P=SYS\$S&P!$S) O8++P33ZSH
M&10O=P4+^%3*^9QD8 EZ#OY.F\Z/*,$!] 6OQD>07E/0-1D#\/,H0X':S0SH
M'#]%R!8Y3:Y(F)GQ!R!OXAKN"R)_$(7@H0>H>8"UP)F]YP\&81ED0LS!F?U%
MX$]_ :8 D6FP-Q-/C-B[+\*9D[3X?33R'%@5#IV)$-AB3B@2)_Y#T>AQGS)Z
M\-"+AD\&";4:/N\+7&K1M,+CI^:7 7A/2+[X\ O\^<B+8C" (OJ NU/81 RT
M"ZL($%-B-HG06$LQMR\C"N#QHX#%A-3Z $J#W2,U@+CR$/UT+(^(^#[R$M@S
M&X&$&P)QL5$43C.>&H6^'][C<T1\D6A<OW_+ID*2M>(,*:( JPA)(@74>!P=
M CXCI(%/"+*$.5$8QZ 0,.0Q=Q^DX+WW?#10 2I3A(6$6B A.YW[DISP#6X8
M8P0(!/@8",07W"WRA7<7)O"C#[^HM0%_(#ZMYG??M.W+N@C!]<&19;^M2CM>
M[R>M>)H>*$]02NAC^@\&, 3*3-!HJ>QR)D)\-A8Y!#3M'-ESA#YID1C@-ZGC
MBG;!4 1_A_(#)"!4#J10D9M 28-(6>0B$"0"9 ]*LPC(&]\DO+_GD92\L?!!
M @@7!?,(E4P8/61&@11K\!Y?S.('U,&Q#$R"$ ?X!3&)I7=OX<%)2.SA17)'
M0-P)B5VP58H'D"Q#.V'#<)[0"L#4L.,XWQE#?K_SDH<F6DOLC3)]AL+W!%KX
MQ$A%]392V@&6&$I)]*EYTV0_A:%+O/0VFH_9E8)V),%Z 0PO'3EZ5FHO>#.Z
M]X9D4Q'0:3GH)Q!0P,83U "PXPQ 2:ADBV!3%$"TC5GDD?[)T ![DB8-J3T0
M9(AS^+QH5@&[X[<85V!!&("W<<=C7!?W[P4!J#Z2+?FJ2".T?XD@7"3%;+-@
M;P(M%@S%#&KHY*+,\@%9@5HZE(=(7TWB-@Q B>-A#2F5/%1(H%+(=\[H%U\!
M>HJY$?PNR&S-!8&-D$*9-18^+15P4),LGD6@$ND<BV17H,>4 D'07TE<,+0Y
M%7,H)8\_A8]G*=O Z5'2AD O09@BEJ&V174:I+R(9@KH$!+PF8F,VXO$E /7
M2K4-@@&)2VT,+1@\?VH8@44QQ0TA6*?"!<4KC0)X$TGX!S*HP5(U\+-@X2.%
M7P /X9.^ L4#EGO=C=F<!!<B;,3; NP#4&QH\FTP:M&L1YS-T ;!'4D>GLW\
M%+P7[U,&+A UWO"D1/$!.,&)O!D]33__!$=A/PG!KL#\N*"HW4N6($$E3T3O
MD/2R\TR0=\8<Q><L_"R4^;?HN8";+"_#%BQ/97O16:5IAV_[/0)G+\!XLB2_
MM[F+PRY^__W#VY=2Y"7KA.$LC4)SL/K0_@%CW$MY([,#X_D,L!B"]?- G _R
M[K]DR8(L]H;S=',I'SDHZ'AJ-@HWW?@BFV]FZ*)<J9%7MN&V)K==J[39];;(
M)JY3P6IDJX('3<I,F>,.X- C!LCBJQ?+9CLR$?A*\%KPUWRR59X,AI*3*;8W
MYPT&Y*AB&-EI5'PB1G<DFF+<7L5F$^%, H#MV$-"6[ 7LLB$Y C2<#,*%\,I
MN;3\$1[DM33P/G<^1394#L]&7"]=^Z;\]EHZKW=BY2(XO\^DZ[56_A,^1+,O
M6?W)$W?'\L])E(<LQZ(Q!,A^;O 1<-YK[H.G&;_X>E?6E2%X%2<+/\,W: -=
M?/CEY1IG%6CC)X\"'W'J\X%E))TG$(Y(*=FS_XQSSQ:EX..N+8J^!+,?E)@'
M.BNP36-(ENVRS_N$I[N>,Z2>B?E() \8?H-?R<@*_ L\05) "AKN0P# =F+4
M<B_!*.$Q6?S+88 PSGP2,.T#%PT;5!LD_HL! H-M=3-"!GLL<DLJ=0HRVPZ5
M#D?_ 4-$,KJ%KU@($( '0>K&0U@!JD%DS2-E:>5"9@5J3?;O\!Z%C9%+L/MP
M[KMK/010P0:N$=YCL%7I/8R)@2T'* 8''[UZ,'ACC(&J? RP)E0DZHL'N!8J
M[H'T2K"0E$HXI: 8&CCPYQ1^17:DQ'T(TA.L:VE"Y)X!FN,%_V'%D@1C$6@
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M!QVURCG%6X&]Z:Q=07+(/D);JJVV15*V;2]Y.T=27G5A- 6\@511UBJC;=-
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ML/4%R2$O2/3%R'I"M#J@J79,M- W(S5 L&D:[7[9CN(UNQJIB/Q97ZG[!IZ
MO8K P5K=B_=A(D!HOMPHA<H51&_&R[&K.W<>[):NO%MI_+:RH.YKG!;KK!=>
M-YN+VG41] E%=-Z$TVD8,.IA8+!O6\U6RV0S'K$[[L]%DUW-DTD8P8(NLSHM
M S:#_Y?#E+$<?G#);/BHWS8LNT/M$-HVUD 95L=63S$OCK%NCP8\S),X@;\
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ME@@*!K5;QA9S$$X6/._ADQ+0>2X5%3RD39DACX48*PA JV69VPS2V"81YKS
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M4#484/MJ&+H/\)]),O5_^/]02P$"% ,4    " ""AF)3:]]N6804  #?D
M$0              @ $     87%S="TR,#(Q,3$P,BYH=&U02P$"% ,4
M" ""AF)3'_Q-L'("  !Q!P  $0              @ &S%   87%S="TR,#(Q
M,3$P,BYX<V102P$"% ,4    " ""AF)3[<X>$IL*  "/80  %0
M    @ %4%P  87%S="TR,#(Q,3$P,E]L86(N>&UL4$L! A0#%     @ @H9B
M4X/JT*O@!@  ?3,  !4              ( !(B(  &%Q<W0M,C R,3$Q,#)?
M<')E+GAM;%!+ 0(4 Q0    ( (*&8E/>=$-?^3D  !TS P 6
M  "  34I  !A<7-T+7$S>#(P,C%X97@Y.3$N:'1M4$L%!@     %  4 2 $
' &)C      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
